| Literature DB >> 34194429 |
Laura Pandolfi1, Sara Bozzini1, Vanessa Frangipane1, Elena Percivalle2, Ada De Luigi3, Martina Bruna Violatto3, Gianluca Lopez4, Elisa Gabanti2, Luca Carsana4, Maura D'Amato1,5, Monica Morosini1, Mara De Amici6, Manuela Nebuloni4, Tommaso Fossali7, Riccardo Colombo7, Laura Saracino8, Veronica Codullo9, Massimiliano Gnecchi10,11, Paolo Bigini3, Fausto Baldanti2, Daniele Lilleri2, Federica Meloni1,12,13.
Abstract
The release of neutrophil extracellular traps (NETs), a process termed NETosis, avoids pathogen spread but may cause tissue injury. NETs have been found in severe COVID-19 patients, but their role in disease development is still unknown. The aim of this study is to assess the capacity of NETs to drive epithelial-mesenchymal transition (EMT) of lung epithelial cells and to analyze the involvement of NETs in COVID-19. Bronchoalveolar lavage fluid of severe COVID-19 patients showed high concentration of NETs that correlates with neutrophils count; moreover, the analysis of lung tissues of COVID-19 deceased patients showed a subset of alveolar reactive pneumocytes with a co-expression of epithelial marker and a mesenchymal marker, confirming the induction of EMT mechanism after severe SARS-CoV2 infection. By airway in vitro models, cultivating A549 or 16HBE at air-liquid interface, adding alveolar macrophages (AM), neutrophils and SARS-CoV2, we demonstrated that to trigger a complete EMT expression pattern are necessary the induction of NETosis by SARS-CoV2 and the secretion of AM factors (TGF-β, IL8 and IL1β). All our results highlight the possible mechanism that can induce lung fibrosis after SARS-CoV2 infection.Entities:
Keywords: COVID-19; NETosis; SARS-CoV2; epithelial-mesenchymal transition; lung fibrosis
Mesh:
Year: 2021 PMID: 34194429 PMCID: PMC8236949 DOI: 10.3389/fimmu.2021.663303
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Analysis of BAL COVID-19 patients. (A) Quantification of NETs in BAL of mild (IMW) and severe (ICU) patients. NETs were measured by free-DNA quantification reading absorbance at 415 nm. (B) Quantified NETs were compared dividing samples in survivors and non-survivors. (C) Correlation analysis between NETs and percentage of neutrophils counted in the respective BAL sample. (D) Correlation analysis between NETs and IL8 quantified in the respective BAL sample. Data are represented as median (IQR). *p < 0.05; ^p = 0.05. r = Spearman coefficient.
Figure 2Morphological and immunohistochemical clues of EMT in lung tissue of patients which died of COVID-19, with DAD in proliferative phase. (A) At low power, oedema, vascular congestion, hemorrhage, and inflammatory infiltrates are visible (H&E, 10x). (B) At higher magnification, hyperplastic pneumocytes, a few granulocytes and fibrin deposition are evident (H&E, 40x). (C) Double IHC for an epithelial marker, CK7 (red) and a mesenchymal marker, α-SMA (brown) demonstrated co-expression in a subset of alveolar reactive pneumocytes (40x). (D) At higher magnification, a gradient of CK7 loss can be observed within the epithelial cells, and a subset co-expresses CK7 (red) as well as α-SMA (brown) (100x). (E) IHC for E-cadherin highlights partial loss in epithelial cells, some of which demonstrate a spindle morphology (inset) (40x, inset 100x). (F) IHC for α-SMA demonstrated the presence within epithelioid cells (40x, inset 100x).
Figure 3(A) Representative immunoblots of A549 treated with different conditions for 48 h. Membrane was immunodecorated with antibodies specific for E-Cadherin, α-SMA and β -actin. (B) Quantification of immunoblots of A549 using anti-E-cadherin or anti-α-SMA incubated with 2.5 x 106 PMA-Neu or NETs isolated from 2.5 x 106 PMA-Neu after 24 h. (C) RT-PCR analysis of RNA extracted by A549 treated with PMA-Neu or NETs for 24 h. Data are represented as mean ± SD of three independent replicates. ***p < 0.001 vs. CTR.
Figure 4(A) Representative immunoblots of A549 treated with different conditions for 48 h. Membrane was immunodecorated with antibodies specific for E-Cadherin, α-SMA and β -actin. (B) Semiquantitative analysis of immunoblots and (C) RT-PCR analysis of airway in vitro model cultured with SARS-CoV2, AM+SARS-CoV2, Neu+SARS-CoV2 or Neu+AM+SARS-CoV2 after 48 h of treatment. (D) NETs quantification by CitH3 ELISA. (E) TGF-β quantification by ELISA assay. Data are represented as mean ± SD. ***p < 0.001 vs. CTR; *p < 0.05 vs. CTR; **p < 0.01 vs. CTR.